Takara Bio

Basic Information

Stock Code
4974
Industry
Chemicals
Category Detail
Biotechnology & Pharmaceuticals
Prefecture
Shiga Prefecture
Establishment Year
April 2002
Listing Year
December 2004
Official Website
https://www.takara-bio.co.jp/
TSE Information
TSE Information
Yahoo! Finance
Yahoo! Finance
Other Companies
GN I Group, Heartseed, Takara HD, Ono Pharmaceutical, AnGes, Nexela Pharma, PeptiDream, SanaBio, Helios, RenaScience, Noil, QualiPs, Japan Tissue Engineering

Overview

Takara Bio is a biotechnology company established in 2002, centered on genetic engineering technology to develop reagents and medical food businesses, and is a leading industry player with technological strength and a unique product lineup both domestically and internationally.

Current Situation

Takara Bio recorded consolidated net sales of approximately 67.7 billion yen, operating income of approximately 28.9 billion yen, and net income of approximately 19.9 billion yen for the fiscal year ended March 2022, maintaining a stable financial base. Centered on research reagents for genetic engineering and research consignment services, it maintains competitiveness in the pharmaceutical field. It is advancing international technological collaborations such as the acquisition of the U.S. Clontech business and the introduction of iPS cell-related technologies. In 2021, it launched novel coronavirus PCR testing reagents, demonstrating market responsiveness. In medical food bio, it diversifies with mushroom and fucoidan-related products, expanding its business scope. It engages in environmentally considerate initiatives and regional contributions aligned with sustainable development goals. Moving forward, it aims for growth by strengthening R&D in drug discovery and cell therapy, leveraging new technologies, and pursuing global expansion. While addressing technological competition with major competitors and regulatory changes, it focuses on business diversification.

Trivia

Interesting Facts

  • Originated from the biotechnology division of Takara Shuzo, with a historical technological foundation
  • Pioneered industry with artificial culture research for matsutake and honshimeji mushrooms
  • Accelerated global expansion by integrating overseas technology through Clontech acquisition
  • Became key player in drug discovery field by licensing iPS cell-related technologies
  • Gained attention for social contribution during COVID-19 through PCR testing reagent development
  • Takara Holdings as major shareholder provides stable funding base
  • Known as one of Japan's leading providers of bio research consignment services
  • Secured numerous licenses for RetroNectin used in gene therapy
  • Maintains market competitiveness through diverse brand deployment in research reagents
  • Mushroom business transferred to Yukiguni Maitake in 2018, implementing business restructuring

Hidden Connections

  • Unique corporate background fusing sake brewing and bio research under Takara Holdings
  • Collaboration with global bio firms through Clontech business acquired from U.S. BD
  • Exclusive use of cardiomyocyte production technology through partnership with Kyoto University iPS Cell Institute
  • Participation in joint gene vaccine development with domestic pharma ventures like AnGes
  • Built strong network with domestic medical institutions through rapid PCR testing reagent deployment
  • Differentiation through dual axes of fucoidan food products and gene therapy technology
  • Overseas network with subsidiaries in U.S., Europe, India, Korea, and China
  • Handles gene analysis equipment, establishing integrated equipment and reagent supply system

Future Outlook

Growth Drivers

  • Expanding demand for cell culture and therapy technologies in regenerative medicine
  • Higher precision and lower costs in next-generation gene analysis technologies
  • Continued growth in medical reagent market
  • Active entry into iPS cell-related drug discovery
  • Expansion of functional food market due to rising health consciousness
  • Growth in global biopharmaceutical market
  • Promotion of clinical development for new gene therapies
  • Advancement of technological innovations through research institution partnerships
  • Strengthened utilization of digital transformation
  • Establishment of sustainable manufacturing processes

Strategic Goals

  • Achieve 20% global market share in gene therapy products
  • Expand iPS cell-related business sales to 10 billion yen scale
  • Diversify and expand functional food material business
  • Achieve company-wide carbon neutrality
  • Expand consignment research service partnerships to over 50 countries
  • Acquire 10 or more patents for new bio products
  • Build diverse talent development system and improve employee satisfaction
  • Establish sustainable supply chain
  • Improve production efficiency by 30% through advanced manufacturing technologies
  • Promote 20 or more joint research projects with medical and research institutions

Business Segments

Research Reagent Sales

Overview
Provides high-quality molecular biology reagents to researchers across a wide range of fields.
Competitiveness
Advanced genetic engineering technology and extensive patented products
Customers
  • University research institutions
  • Pharmaceutical companies
  • Biotechnology ventures
  • Public research institutes
  • Private R&D centers
Products
  • PCR reagents
  • Enzyme products
  • DNA/RNA extraction kits
  • Antibody reagents
  • Cell culture reagents

Consignment Research Services

Overview
Provides specialized consignment services for gene analysis and cell experiments.
Competitiveness
World-class analysis technology and extensive track record
Customers
  • Pharmaceutical companies
  • Biotech firms
  • University research groups
  • Clinical testing institutions
Products
  • Genome analysis services
  • Gene synthesis & editing
  • Cell function analysis
  • Pharmacology test support

Gene Therapy & Cell Therapy

Overview
Supplies innovative gene and cell therapy products and provides technical support.
Competitiveness
Advanced clinical trial support and patented technologies
Customers
  • Pharmaceutical companies
  • Medical institutions
  • Regenerative medicine ventures
Products
  • RetroNectin licensing
  • Cell culture technology support
  • Gene therapy drug materials

Healthcare Food Material Supply

Overview
Stably supplies functional materials to the processed food industry.
Competitiveness
Proprietary raw material extraction methods and quality control
Customers
  • Health food manufacturers
  • Pharmaceutical companies
  • Food processors
Products
  • Fucoidan extracts
  • Ashitaba chalcone
  • Agar-derived oligosaccharides

Equipment & Analysis Devices

Overview
Provides gene testing equipment for research and diagnostics.
Competitiveness
Balance of high sensitivity and ease of use
Customers
  • University labs
  • Testing institutions
  • Medical corporations
Products
  • Real-time PCR devices
  • Gene testing equipment
  • Centrifuges

Competitive Advantage

Strengths

  • Advanced genetic engineering technology
  • Abundant patents and unique product lineup
  • Global technology partnership network
  • Strong brand in research reagent field
  • Diversified business and revenue base
  • Advanced medical reagent development capabilities
  • Stable capital base and sales growth
  • Comprehensive consignment analysis service resources
  • International clinical trial support track record
  • High-quality health food materials
  • Robust quality control and manufacturing system
  • Collaboration with researcher community
  • Long track record and reliability
  • Diverse sales channel network
  • Rapid market response capabilities

Competitive Advantages

  • Top-class domestic market share in genetic engineering research reagents
  • Strengthened international expansion through integration of U.S. Clontech business
  • Exclusive usage rights for iPS cell-related technologies
  • Pioneering new gene therapy market with RetroNectin
  • Entry into medical food market with proprietary mushroom culture technology
  • Technology penetration via diverse international partnerships and licenses
  • Integrated provision of research equipment and reagents
  • Gained trust through quality and safety of health food materials
  • Promotion of advanced cell therapy-related technologies
  • Flexible customization services responding to market needs
  • Rapid new product development and patent protection
  • Secured broad customer base and sustainable growth
  • Strong relationships with pharmaceuticals and research institutions
  • Broad customer touchpoints via diverse sales channels
  • Gained trust in medical market through rapid launch of novel coronavirus PCR products

Threats

  • Intense international competition in bio-pharmaceuticals
  • Risk of patent infringement or technology leakage
  • Product approval delays due to new regulations
  • Decline in demand from fluctuating research funding
  • Revenue instability from exchange rate fluctuations
  • Advances in competitors' innovative technologies
  • Market disruptions from global pandemics, etc.
  • Rising raw material prices and supply risks
  • Expiration or renewal issues with intellectual property rights
  • Burden of stringent safety regulations for medical products
  • Reputation risks from quality issues in health food market
  • Challenges in talent acquisition and technology succession

Innovations

2021: Launch of COVID-19 PCR Testing Reagents

Overview
Developed and launched PCR testing reagents for novel coronavirus in Japan.
Impact
Contributed to faster testing and gained trust in medical settings

2022: Introduction of iPS Cell-Derived Cardiomyocyte Differentiation Technology

Overview
Acquired exclusive usage rights to technology from Kyoto University iPS Cell Research Institute.
Impact
Succeeded in producing cardiomyocytes for drug discovery, expanding market

2023: Enhancement of Next-Generation Gene Analysis Services

Overview
Launched new services applying high-precision shotgun analysis technology.
Impact
Contributed to increased consignment analysis sales

2024: Commercial Expansion of Artificial Mushroom Culture Technology

Overview
Improved Hatakeshimeji and Honshimeji culture technology for higher productivity.
Impact
Achieved share expansion in medical food market

2022: RetroNectin License Agreement Renewal

Overview
Continued acquisition of exclusive supply contract for U.S. clinical trial support drug.
Impact
Secured stable revenue source in gene therapy field

Sustainability

  • Promotion of energy-saving measures at factories to reduce environmental impact
  • Implementation of educational support programs through collaboration with local communities
  • Efforts in sustainable product development and safety improvements
  • Diverse talent recruitment and creation of a comfortable work environment
  • Recycling and reduction activities for product waste